Metabolite Changes in the Aqueous Humor of Patients With Retinal Vein Occlusion Macular Edema: A Metabolomics Analysis

Xiaojing Xiong1, Xu Chen1, Huafeng Ma1, Zheng Zheng1, Yazhu Yang1, Zhu Chen1, Zixi Zhou1, Jiaxin Pu1, Qingwei Chen2 and Minming Zheng1*

1Department of Ophthalmology, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China, 2Department of general practice, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

Macular edema (ME) is the main cause of visual impairment in patients with retinal vein occlusion (RVO). The degree of ME affects the prognosis of RVO patients, while it lacks objective laboratory biomarkers. We aimed to compare aqueous humor samples from 28 patients with retinal vein occlusion macular edema (RVO-ME) to 27 age- and sex-matched controls by ultra-high-performance liquid chromatography equipped with quadrupole time-of-flight mass spectrometry, so as to identify the key biomarkers and to increase the understanding of the mechanism of RVO-ME at the molecular level. Through univariate and multivariate statistical analyses, we identified 60 metabolites between RVO-ME patients and controls and 40 differential metabolites in mild RVO-ME [300 μm ≤ central retinal thickness (CRT) < 400 μm] patients compared with severe RVO-ME (CRT ≥ 400 μm). Pathway enrichment analysis showed that valine, leucine, and isoleucine biosynthesis; ascorbate and aldarate metabolism; and pantothenate and coenzyme A biosynthesis were significantly altered in RVO-ME in comparison with controls. Compared with mild RVO-ME, degradation and biosynthesis of valine, leucine, and isoleucine; histidine metabolism; beta-alanine metabolism; and pantothenate and coenzyme A biosynthesis were significantly changed in severe RVO-ME. Furthermore, the receiver operating characteristic (ROC) curve analysis revealed that adenosine, threonic acid, pyruvic acid, and pyro-L-glutaminyl-L-glutamine could differentiate RVO-ME from controls with an area under the curve (AUC) of >0.813. Urocanic acid, diethanolamine, 8-butanolineosolaniol, niacinamide, paraldehyde, phytosphingosine, 4-aminobutyraldehyde, dihydrolipoate, and 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide had an AUC of >0.848 for distinguishing mild RVO-ME from severe RVO-ME. Our study expanded the understanding of metabolomic changes in RVO-ME, which could help us to have a good understanding of the pathogenesis of RVO-ME.

Keywords: retinal vein occlusion, macular edema, macular central thickness, aqueous humor, metabolomics analysis

ORIGINAL RESEARCH

Edited by: Wei Chi, Sun Yat-sen University, China
Reviewed by: Chuntao Lei, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, China, Du Liping, Chongqing Eye Institute, China, Wenru Su, Sun Yat-sen University, China
*Correspondence: Minming Zheng; 381393002@qq.com

Specialty section: This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology

Received: 22 August 2021
Accepted: 26 November 2021
Published: 21 December 2021

Citation: Xiong X, Chen X, Ma H, Zheng Z, Yang Y, Chen Z, Zhou Z, Pu J, Chen Q and Zheng M (2021) Metabolite Changes in the Aqueous Humor of Patients With Retinal Vein Occlusion Macular Edema: A Metabolomics Analysis. Front. Cell Dev. Biol. 9:762500. doi: 10.3389/fcell.2021.762500
INTRODUCTION

Retinal vein occlusion (RVO) is the major cause of vision loss by retinal vascular diseases. Classified by the location of obstruction, RVO can be differentiated into central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO). Known risk factors for RVO include hypertension, atherosclerosis, hyperlipidemia, diabetes, thrombosis, and other inflammatory and myeloproliferative diseases (Petr, 2014; Balaratnasingam et al., 2016). Clinical presentations of RVO include retinal hemorrhage, tortuous retinal veins, optic nerve swelling, and macular edema (ME) (Querques et al., 2013). Among them, the most common cause of vision loss in RVO is ME. Studies have shown that central retinal thickness (CRT) was closely related to visual acuity and prognosis (Eng and Leng, 2020). Although the diagnosis of retinal vein occlusion macular edema (RVO-ME) was undoubted, the initial pathogenesis and following pathophysiology of RVO-ME remained controversial.

Abundant metabolomics studies have been carried out in animal models or humans under pathophysiological conditions to identify the most important metabolites in various ophthalmic diseases by analyzing blood or intraocular fluid samples (Deng et al., 2020). Aqueous humor (AH) provides nutrition for the surrounding avascular cornea and lens and discharges the metabolic waste from the eyes to the venous blood. The metabonomic information of AH could directly reflect the physiological state of the eyes (Haines et al., 2018). Recent studies using liquid chromatography−mass spectrometry (LC-MS) have also identified almost 250 metabolites belonging to 47 metabolic pathways in AH (Karolina et al., 2017). Additionally, wet age-related macular degeneration (Han et al., 2020), diabetic retinopathy (Pietrowska et al., 2018), severe myopia (Ji et al., 2017), primary open-angle glaucoma (Buisset et al., 2019), and primary congenital glaucoma (Breda et al., 2020) were also found to be associated with metabolomic signatures in the aqueous humor. However, AH metabolism of RVO-ME has not been reported yet.

The aims of the current study were to identify differential metabolites in the RVO-ME compared with controls, to screen biomarkers from these differential metabolites, and to identify potential biomarkers that could differentiate patients between mild RVO-ME (mRVO-ME) (300 μm ≤ CRT < 400 μm) and severe RVO-ME (sRVO-ME) (CRT ≥ 400 μm) (Kim et al., 2020) (Figure 1).

METHODS

Sample Collection

The study was conducted in accordance with the requirements of the Ethics Committee of The Second Affiliated Hospital of Chongqing Medical University, which approved the study (2020405). The study follows the principles of the Helsinki Declaration. All aqueous humor samples from patients with RVO-ME (n = 28) and the age- and sex-matched control group (n = 27) were collected from ophthalmology department of the Second Affiliated Hospital of Chongqing Medical University, from October 2020 to March 2021. All participants were informed and signed the informed consent.

Cataract grading had been assessed using the Lens Opacities Cataract Classification System III (LOCS III) (Chylack et al., 1993). LOCS III of both the RVO group and the control group were N2C2P2. The diagnosis of RVO was made using the International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM). CRVO was defined as ICD-9 362.35 and BRVO as ICD-9 362.36 (Kupka, 1978). The inclusion criteria for RVO-ME were as follows: 1) age ≥18 years, 2) diagnosis within 1 year, and 3) CRT ≥ 300 μm. Exclusion criteria included the following: 1) age-related macular degeneration; 2) diabetic retinopathy; 3) previous intravitreal injection of anti-vascular endothelial growth factor or steroids; 4) previous intraocular surgery; 5) previous retinal photocoagulation; 6) glaucoma, including neovascular glaucoma; 7) iris redness and anterior chamber hemorrhage; 8) vitreous hemorrhage and other vitreoretinal disease; 9) cerebrovascular accident or myocardial infarction in the past 3 months; and 10) any kind of eye drops has been used within 3 months prior to sample collection. Samples of the control group were set as follows: sheath gas flow rate at 30 Arb, Aux gas flow rate at 25 Arb, capillary temperature 350°C, full MS resolution at 60,000, MS/MS resolution at 7,500, collision energy at 10/30/60 in NCE mode, and spray voltage at 3.6 kV (positive) or −3.2 kV (negative), respectively.

Data Processing
The raw data was converted to the mzXML format using ProteoWizard and processed with an in-house program, which was developed using R and based on XCMS, for peak detection, extraction, alignment, and integration. Then, an in-house MS2 database (BiotreeDB) was applied in metabolite annotation. The cutoff for annotation was set at 0.3.

Then, we performed principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) by using SIMCA version 16.0.2 (Umetrics AB, Sweden) to obtain an overview of metabolomics data. The contribution of each metabolite was calculated according to the PLS-DA model and expressed as variable importance in the prediction (VIP) score. To evaluate the significance of metabolites, the metabolites with a VIP score >1 were analyzed by Student’s t-test. The categories of metabolites were defined by using the Human Metabolome Database (HMDB) (https://hmdb.ca/).

Bioinformatics Analysis
Volcano plots were made using GraphPad Prism V.7.0.0. Meanwhile, we calculated the Euclidean distance matrix for the quantitative value of differential metabolites and clustered the differential metabolites by complete linkage method. Then, we mapped authoritative metabolite databases such as KEGG and PubChem through differential metabolites. After obtaining the matching information of differential metabolites, we searched the pathway database of the corresponding species Homo sapiens (human) and conducted an enrichment analysis and a topological analysis to find the most critical pathways that are most related to differential metabolites.

Receiver Operating Characteristic Curve Analysis
To identify potential diagnostic biomarkers, a receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic potential of differential metabolites, and the area under the curve (AUC) was calculated.

Statistical Analysis
SPSS 22.0 was used to analyze the data. The results were expressed as mean ± standard deviation (SD) of continuous variables. The normality was tested by Shapiro–Wilk test. Student’s t-test, ANOVA, Fisher’s exact test, and Pearson chi square test were used. A p value <0.05 was considered statistically significant.

RESULTS
Clinical Characteristics of Participants
To investigate the metabolic profile of aqueous humor in RVO-ME, we enrolled 27 age- and sex-matched controls and 28 RVO-ME patients (11 mRVO-ME, 300 μm ≤ CRT < 400 μm,
TABLE 1 | Demographic and clinical characteristics of participants.

|                  | RVO-ME (28) | Control (27) | p value* |
|------------------|-------------|--------------|----------|
|                  | mRVO-ME (11) | sRVO-ME (17) |          |
| Gender (male/female) | 5/6         | 8/9          | 12/15    | 0.986    |
| Age (years), median | 70 ± 8.35   | 70.12 ± 8.03 | 70.33 ± 8.06 | 0.992    |
| BMI (kg/m²)       | 23.2 ± 1.73 | 23.3 ± 1.82  | 22.86 ± 2.03 | 0.753    |
| Hypertension (yes/no) | 3/8         | 13/4         | 19/8     | 0.907    |
| Diabetes (yes/no)  | 2/9         | 3/14         | 4/23     | 0.956    |
| Coronary heart disease (yes/no) | 2/9         | 3/14         | 5/22     | 0.997    |
| Hyperlipidemia (yes/no) | 4/7         | 6/11         | 9/18     | 0.981    |

RVO-ME, retinal vein occlusion macular edema; mRVO-ME, mild retinal vein occlusion macular edema; sRVO-ME, severe retinal vein occlusion macular edema.

*P-value was calculated by Student’s t-test.

There was no significant difference in age, gender, hypertension, coronary heart disease, and diabetes mellitus among the groups (Table 1).

**AH Metabolism Analysis**

In order to identify the metabolism of aqueous humor, untargeted metabolomics analysis was applied. The results showed that the method had good reproducibility, and only slight changes of the spectral peaks of the QC samples were found (Supplementary Figure S1). A total of 4,945 signals were identified by peak alignment, missing value reconstruction, and data normalization. After Pareto scaling the data, PCA models displayed that QC samples were closely clustered (Supplementary Figure S2), which also indicated the high repeatability of the method and the reliability of the data. In order to visualize and identify the most prominent metabolic differences among the various groups, PLS-DA was performed. Using median coordinates for the training set, the scatter plot of the latent variables of the PLS-DA models showed good discrimination for comparisons between RVO-ME versus controls and mRVO-ME versus sRVO-ME (Figure 2).

**Differentially Expressed Metabolites Between Groups**

A total of 60 differential metabolites were found in RVO-ME when compared with controls and 40 differential metabolites in mRVO-ME compared with sRVO-ME (VIP > 1 and p < 0.05), including amino acids, carboxylic acids, fatty acid purine, pyrimidine, and so on (Table 2). Volcano plots (Figure 3), heat plot, and hierarchical cluster analysis (Figure 4) were used to investigate variation tendencies for the differential metabolites. Twenty-two metabolites were significantly elevated and 38 metabolites were significantly decreased in RVO-ME compared to controls. We also found 30 increased metabolites and 20 decreased metabolites when comparing mRVO-ME with sRVO-ME (Table 3). When comparing RVO-ME patients with controls, a total of three differential pathways were found, namely, valine, leucine, and isoleucine biosynthesis; pantothenate and coenzyme A (CoA) biosynthesis; and ascorbate and aldarate metabolism. Valine, leucine, and isoleucine biosynthesis; pantothenate and CoA biosynthesis; beta-alanine metabolism; histidine metabolism; and valine, leucine, and isoleucine degradation were altered in sRVO-ME when compared to mRVO-ME (Figure 5).

**ROC Curve Analysis**

Further screening of the metabolic indicators was conducted by ROC analysis (Figure 6). As shown in Figure 6A, threonic acid, pyro-L-glutaminyl-L-glutamine, adenosine, and pyruvic acid had an AUC ≥ 0.813 for distinguishing RVO-ME from controls. When comparing sRVO-ME with mRVO-ME patients, the ROC analysis showed that nine metabolites had an AUC ≥ 0.848, including urocanic acid, 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide, phytosphingosine, niacinamide, 8-butanoylneosolaniol, dihydriopioate, paraldehyde, 4-aminobutyraldehyde, and diethanolamine (Figure 6B).

**DISCUSSION**

In the present study, we explored the metabolomic changes in AH of patients with RVO-ME disease. To the best of our knowledge, this is the first time that UHPC-Q-TOF/MS was used to analyze the discrepancy of AH metabolomics in RVO-ME versus controls and mRVO-ME versus sRVO-ME. After correction, 60 and 40 metabolites were differentially expressed in RVO-ME versus controls and mRVO-ME versus sRVO-ME, respectively. Notably, amino acids were the most abundant differential metabolite category. Also, significant alterations were noted in several metabolic pathways. Interestingly, we found that pantothenate and CoA biosynthesis and valine, leucine, and isoleucine biosynthesis were significantly altered both in RVO-ME versus controls and mRVO-ME versus sRVO-ME. Additionally, ROC curves were also performed to assess the metabolites of AH, which could best distinguish RVO-ME from the controls and mRVO-ME from sRVO-ME.
occurrence and progression of ocular complications in patients with RVO (An et al., 2021; Yong et al., 2007). In the current study, many inflammation-related metabolites have also been found in RVO-ME when compared with controls. Adenosine is an endogenous purine nucleoside, which is widely distributed in the body and interacts with G-protein-coupled receptors (Sebastião and Ribeiro, 2009; Santiago et al., 2020). Under the stress conditions of tissue ischemia, hypoxia, and inflammatory response, the concentration of extracellular adenosine increased exponentially. Previous studies have shown that adenosine or its analogues could raise intraocular angiogenic factors and inflammatory cytokines, such as vascular endothelial growth factor, insulin-like growth factor-1, basic fibroblast growth factor, interleukin-8, and angiogenin-2 (Feoktistov et al., 2003; Haskó and Pacher, 2012). Luo et al. (2019) found that adenosine attenuated the inflammatory response of human endothelial cells through negative regulation of Toll-like receptor MyD88 signal. Haas et al. (2011) showed that adenosine could induce a reduction of Toll-like receptor4 expression at the surface of human macrophages, resulting in a robust inhibition of TNF-α production. In this study, compared with the controls, the level of adenosine in RVO-ME increased, which suggests that RVO-ME was associated with inflammatory process, to some extent. In addition, adenosine also regulates vascular tension and thus blood flow. Adenosine, acting predominantly at A2aR, induced the production of NO, which causes vasodilation of retinal vessels (Riis-Vestergaard et al., 2014; Riis-Vestergaard and Bek, 2015). We speculated that the decrease of A2aR also resulted in the increase of free adenosine, which might play a crucial role in RVO vascular occlusion. Threonic acid, also known as threonate, is a central signaling hub in ascorbate–aldarate pathway (Wang et al., 2019). We detected an abnormal expression of threonine and ascorbate and aldarate metabolism in RVO-ME. As shown by the experiment of corneal neovascularization in a rodent model, ascorbic acid might inhibit angiogenesis, which was regarded as a vital event of RVO (Ashino et al., 2003). In our present study, we also found that adenosine and threonic acid could act as a potential

FIGURE 2 | Orthogonal projection to latent structures-discriminant analysis of aqueous humor metabolomic data.
| Metabolites | TABLE 2 | Identified differential metabolites. | Category |
|-------------|---------|-------------------------------------|----------|
| Ketoleucine  | 1.158  | 0.80  | 0.034 | 1.86  | 0.68  | 0.012 | Amino acids |
| Cis-4-Hydroxy-o-proline | 1.71 | 0.70 | 0.030 | 1.43 | 0.89 | 0.022 | Amino acids |
| 8-Butanoylneosolaniol | 1.66 | 7.98 | 0.008 | 2.38 | 10.97 | 0.007 | Fatty acid |
| Dihydropyracil | 1.87 | 0.74 | 0.004 | 1.47 | 0.88 | 0.030 | Pyrimidines |
| L-trans-4-methyl-2-pyrrolidinecarboxylic acid | 1.06 | 2.04 | 0.033 | 1.06 | 2.04 | 0.033 | Amino acids |
| D-mannose | 1.17 | 1.36 | 0.030 | 1.17 | 1.36 | 0.030 | Carbohydrate |
| Dihydrocolpoate | 2.17 | 1.72 | 0.004 | 2.48 | 2.52 | 0.003 | Fatty acids |
| 1-(beta-D-ribofuranosyl)-1,4-dihyronicotinamide | 1.51 | 0.49 | 0.010 | 1.70 | 0.75 | 0.002 | Carbohydrate |
| D-1-amino-2-pyrrolidinecarboxylic acid | 1.15 | 0.57 | 0.043 | / | / | / | Monoalkyl amines |
| Adenosine | 1.92 | 2.20 | 0.000 | / | / | / | Purine |
| Cuscin | 1.22 | 2.36 | 0.000 | / | / | / | Iridoid o-glycosides |
| Pyruvic acid | 2.01 | 0.38 | 0.001 | / | / | / | Amino acids |
| 1-Methylhypoxanthine | 1.70 | 0.44 | 0.007 | / | / | / | Purine |
| 4-Dodecylbenzenesulfonic acid | 1.12 | 1.36 | 0.030 | / | / | / | Fatty acids |
| 1-(beta-D-ribofuranosyl)-1,4-dihyronicotinamide | 1.51 | 0.49 | 0.010 | 1.70 | 0.75 | 0.002 | Carbohydrate |
| Adenosine | 1.92 | 2.20 | 0.000 | / | / | / | Purine |
| Cuscin | 1.22 | 2.36 | 0.000 | / | / | / | Iridoid o-glycosides |
| Pyruvic acid | 2.01 | 0.38 | 0.001 | / | / | / | Amino acids |
| 1-Methylhypoxanthine | 1.70 | 0.44 | 0.007 | / | / | / | Purine |
| 4-Dodecylbenzenesulfonic acid | 1.12 | 1.36 | 0.030 | / | / | / | Fatty acids |
| 1-(beta-D-ribofuranosyl)-1,4-dihyronicotinamide | 1.51 | 0.49 | 0.010 | 1.70 | 0.75 | 0.002 | Carbohydrate |
| Adenosine | 1.92 | 2.20 | 0.000 | / | / | / | Purine |
| Cuscin | 1.22 | 2.36 | 0.000 | / | / | / | Iridoid o-glycosides |
| Pyruvic acid | 2.01 | 0.38 | 0.001 | / | / | / | Amino acids |
| 1-Methylhypoxanthine | 1.70 | 0.44 | 0.007 | / | / | / | Purine |
| 4-Dodecylbenzenesulfonic acid | 1.12 | 1.36 | 0.030 | / | / | / | Fatty acids |
| 1-(beta-D-ribofuranosyl)-1,4-dihyronicotinamide | 1.51 | 0.49 | 0.010 | 1.70 | 0.75 | 0.002 | Carbohydrate |
| Adenosine | 1.92 | 2.20 | 0.000 | / | / | / | Purine |
| Cuscin | 1.22 | 2.36 | 0.000 | / | / | / | Iridoid o-glycosides |
| Pyruvic acid | 2.01 | 0.38 | 0.001 | / | / | / | Amino acids |
| 1-Methylhypoxanthine | 1.70 | 0.44 | 0.007 | / | / | / | Purine |
| 4-Dodecylbenzenesulfonic acid | 1.12 | 1.36 | 0.030 | / | / | / | Fatty acids |
| 1-(beta-D-ribofuranosyl)-1,4-dihyronicotinamide | 1.51 | 0.49 | 0.010 | 1.70 | 0.75 | 0.002 | Carbohydrate |
| Adenosine | 1.92 | 2.20 | 0.000 | / | / | / | Purine |
| Cuscin | 1.22 | 2.36 | 0.000 | / | / | / | Iridoid o-glycosides |
| Pyruvic acid | 2.01 | 0.38 | 0.001 | / | / | / | Amino acids |
| 1-Methylhypoxanthine | 1.70 | 0.44 | 0.007 | / | / | / | Purine |
| 4-Dodecylbenzenesulfonic acid | 1.12 | 1.36 | 0.030 | / | / | / | Fatty acids |
| 1-(beta-D-ribofuranosyl)-1,4-dihyronicotinamide | 1.51 | 0.49 | 0.010 | 1.70 | 0.75 | 0.002 | Carbohydrate |
| Adenosine | 1.92 | 2.20 | 0.000 | / | / | / | Purine |
| Cuscin | 1.22 | 2.36 | 0.000 | / | / | / | Iridoid o-glycosides |
| Pyruvic acid | 2.01 | 0.38 | 0.001 | / | / | / | Amino acids |
biomarker to distinguish RVO-ME from the controls according to ROC analysis. Therefore, we hold the view that adenosine and threonic acid may play a crucial role in RVO-ME.

When compared with mRVO-ME, we found that the level of D-mannose decreased in sRVO-ME. D-mannose is a natural C-2 epimer of glucose, which can be transported to

Table 2 | (Continued) Identified differential metabolites.

| Metabolites                                      | RVO-ME vs. control | mRVO-ME vs. sRVO-ME | Category         |
|-------------------------------------------------|--------------------|----------------------|------------------|
| Metabolites                                     | VIP    | FC    | p value | VIP    | FC    | p value* |
| Foeniculoside VII                               | /      | /     | /       | 2.56   | 17.16 | 0.012    | Terpene glycosides |
| Piperidine                                       | /      | /     | /       | 1.38   | 0.80  | 0.013    | Piperidines        |
| Urocanic acid                                    | /      | /     | /       | 1.39   | 7.10  | 0.010    | Carboxylic acids   |
| Prolylglycine                                    | /      | /     | /       | 1.29   | 0.28  | 0.012    | Dipeptides         |
| Diethanolamine                                   | /      | /     | /       | 2.58   | 4.47  | 0.004    | 1,2-Aminoalcohols  |
| Isopropylpyrazine                                | /      | /     | /       | 1.51   | 0.74  | 0.008    | Pyrazines          |
| Phytosphingosine                                 | /      | /     | /       | 2.14   | 7.99  | 0.002    | 1,3-Aminoalcohols  |
| Saccharin                                        | /      | /     | /       | 2.41   | 12.29 | 0.008    | Benzothiazoles     |
| 8-Butanoylneosanolanol                          | /      | /     | /       | 2.38   | 10.97 | 0.007    | Fatty acid         |
| 5-Oxo-2(5H)-isoxazolepropanenitrile             | /      | /     | /       | 2.54   | 11.22 | 0.010    | Isoxazoles         |
| Pyrroline                                        | /      | /     | /       | 1.13   | 0.87  | 0.030    | Amino acids        |
| D-Fructosazine                                   | /      | /     | /       | 2.42   | 4.42  | 0.004    | Pyrazines          |
| Paraldehyde                                      | /      | /     | /       | 2.49   | 6.48  | 0.007    | Trioxanes          |
| 1-(beta-D-ribofuranosyl)-1,4-dihydropicolinateamide | /    | /     | /       | 1.70   | 0.75  | 0.002    | Glycosylamines     |
| 5-Amino-3-oxohexanoate                          | /      | /     | /       | 1.07   | 2.10  | 0.049    | Medium-chain keto acids |
| D-1-amino-2-pyrrolinedicarboxylic acid           | /      | /     | /       | 1.15   | 0.79  | 0.034    | Amino acids        |
| 2-(Methylthio)-3H-phenoxazin-3-one               | /      | /     | /       | 2.00   | 0.40  | 0.003    | Phenoxazines       |
| Ribothymidine                                    | /      | /     | /       | 1.87   | 0.41  | 0.006    | Pyrimidine nucleosides |
| Adipic acid                                      | /      | /     | /       | 2.42   | 2.99  | 0.012    | Fatty acids        |
| L-Agaridoxin                                     | /      | /     | /       | 1.51   | 0.58  | 0.019    | Amino acids        |
| N-Acetylt-alanine                                | /      | /     | /       | 1.27   | 0.38  | 0.008    | Amino acids        |
| 4-Aminobutyraldehyde                            | /      | /     | /       | 2.49   | 2.93  | 0.007    | Alpha-hydrogen aldehydes |
| N-Acetylt-serine                                 | /      | /     | /       | 1.38   | 0.72  | 0.013    | Amino acids        |
| 3-Furoic acid                                    | /      | /     | /       | 2.03   | 0.36  | 0.042    | Furoic acids       |
| 1-Methylhistamine                                | /      | /     | /       | 1.10   | 0.74  | 0.032    | 2-Arylethylamines  |
| Aceton                                           | /      | /     | /       | 1.74   | 2.75  | 0.035    | Acetoins           |
| N-acetyldopamine                                 | /      | /     | /       | 1.66   | 0.45  | 0.001    | Catechols          |
| LysoPE (1:0:22:2 (13Z,16Z))                      | /      | /     | /       | 2.39   | 34.45 | 0.017    | Phosphoethanolamines |
| LysoPC(18:2) (6Z,12Z))                           | /      | /     | /       | 2.43   | 9.26  | 0.019    | Phosphocholines    |
| Tylosin                                          | /      | /     | /       | 2.55   | 82.48 | 0.045    | Aminoglycosides    |

RVO-ME, retinal vein occlusion macular edema; mRVO-ME, mild retinal vein occlusion macular edema; sRVO-ME, severe retinal vein occlusion macular edema; VIP, variable importance in the projection; FC, fold change.

*P-value was calculated by Student's t-test.

FIGURE 3 | Volcano plots of aqueous humor metabolomic.
mammalian cells through the plasma membrane to promote the diffusion of glucose transporter (GLUT). Rehak et al. (2010) found that IL-1 was rapidly and strongly up-regulated in the retina and retinal pigment epithelium (to levels 80 times higher than controls) in RVO-ME, whereas D-mannose can inhibit macrophage IL-1 (Torretta et al., 2020) and delay the development of osteoarthritis in vivo by enhancing autophagy activated by the AMPK pathway (Lin et al., 2021). Consequently, we considered that D-mannose supplementation may be a meaningful treatment for macular edema caused by RVO.

Oxidative stress played a momentous role in the occurrence and prognosis of RVO-ME (Chen et al., 2018; Hwang et al., 2020); accordingly, related metabolic abnormalities were also found in our study. Many amino acids expressed differently in our study were also involved in oxidative stress response, such as glycine (Knebel et al., 2012), histidine (Nasri et al., 2020), methionine (Demerchi et al., 2021), N-acetylserine (Kim et al., 2019),

---

**TABLE 3** | The significantly altered pathways in RVO-ME.

| Pathway                                   | RVO-ME vs. controls | sRVO-ME vs. mRVO-ME |
|-------------------------------------------|---------------------|---------------------|
| Valine, leucine, and isoleucine biosynthesis | <0.001 Pyruvic acid; citraconic acid; 4-methyl-2-oxopentanoate | 0.016 L-valine; 4-methyl-2-oxopentanoate |
| Pantothenate and CoA biosynthesis         | 0.016 Dihydrouracil; pyruvic acid | 0.016 Dihydrouracil; L-valine |
| Ascorbate and aldarate metabolism         | 0.043 Pyruvic acid; threonic acid | – – |
| Beta-alanine metabolism                   | – –                 | 0.018 4-Aminobutyraldehyde; dihydrouracil |
| Valine, leucine, and isoleucine degradation | – –                 | 0.035 L-valine; M-4-methyl-2-oxopentanoate |
| Histidine metabolism                      | 0.042 Urocanic acid; 1-methylhistamine |

RVO-ME, retinal vein occlusion macular edema; mRVO-ME, mild retinal vein occlusion macular edema; sRVO-ME, severe retinal vein occlusion macular edema.
P-value was calculated by Student's t-test.
urocanic acid (Jauhonen et al., 2011), cis-4-hydroxy-D-proline (Aswani et al., 2019), et al. We also detected a significant metabolite in nucleotide metabolism: nicotinamide (NAM). NAM, the amide of vitamin B3 and precursor for nicotinamide adenine dinucleotide (NAD+), has a strong antioxidant property and can effectively reduce the damage to cells caused by reactive oxygen species (ROS) during oxidative stress (Mejía et al., 2017). Compared with mRVO-ME, the level of NAM in sRVO-ME was decreased. In addition, the AUC of NAM was found to be 0.848 in the ROC analysis, which could serve as a potential biomarker for differentiation between sRVO-ME and mRVO-ME. We believe that the degree and prognosis of RVO-ME are closely related to oxidative stress response. NAM may become an important prognostic biomarker for the treatment of RVO-ME.

Another interesting finding from our study was that the pantothenate (PA) and CoA biosynthesis and valine, leucine, and isoleucine biosynthesis pathways showed a difference in mRVO-ME versus sRVO-ME and RVO-ME versus controls, respectively. Therefore, we speculated that these two metabolic pathways were not only correlated to the occurrence of RVO-ME but also affected the severity of RVO macular edema. Studies had reported that these two metabolic pathways were associated to oxidative stress. PA can regulate cell membrane CoA synthesis and protect endothelial function from enhanced oxidative stress (Demirci et al., 2014). Many studies had also confirmed that this metabolic pathway was abnormal in a variety of diseases, like diabetic kidney disease (Tao et al., 2020), neurodegeneration (Zizioli et al., 2015), Vogt–Koyanagi–Harada (Xu et al., 2021), et al. Valine, leucine, and isoleucine, namely, branched-chain amino acids (BCAAs), which could over-induce oxidative processes and up-regulate proinflammatory factors (Zhenyukh et al., 2017), are unable to be synthesized by animals. Hence, a variety of pathological changes, such as maple syrup urine disease (MSUD) (Xu et al., 2020), type 2 diabetes (Zeng et al., 2019), and cancer (Peng et al., 2020; Sivanand and Vander Heiden, 2020) could be detected when there is a disorder in BCAA metabolism. Nevertheless, the molecular mechanisms of BCAAs involved in the pathogenesis of RVO-ME-inducing retinopathy remain unknown, thus warranting future research.

We recognized the limitations of our research. Firstly, the sample size of patients was small, due to the difficulty in collecting AH sample from patients and controls. Secondly, obtaining AH samples for the diagnosis of RVO-ME or judgment of severity and prognosis of macular edema is not so practical to perform due to the invasive nature of the procedure. Subsequent studies will recruit more participants and combine serum or urine sample analysis to strengthen the results. Thirdly, owing to geographical limitations, our research was limited to the Chinese Han population. We look forward to get the results of other ethnic samples from other researchers. Last but not the least, further research is needed to shed more light on the exact role of these metabolites and relevant metabolic pathways in the pathogenesis of RVO-ME.

In conclusion, to our knowledge, this study is the first one to provide a comprehensive understanding of the metabolomics of AH in patients with RVO-ME. The results showed that a series of complex and serious metabolic disorders occurred in AH in patients with RVO-ME. Furthermore, we also found significant differences in metabolites between mild macular edema and severe macular edema in RVO-ME patients. Significantly, intraocular angiogenic factors, inflammatory mechanisms, and oxidative stress response may play a prominent role in the occurrence and development of RVO-ME. The above-mentioned results may elucidate the metabolic

**FIGURE 5** | Pathway analysis of differential aqueous metabolites in each group.
biomarkers for the prognosis and novel therapeutic strategies to prevent or delay the development of RVO-ME.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

XX and MZ conceived the idea and designed the study. XX, MZ, HM, ZZ, YY, ZC, and XC contributed to collecting the aqueous humor and clinical data. XX, JP, and ZX performed the experiments. MZ and QC analyzed the data. XX wrote the manuscript. MZ and XC reviewed the data interpretation and edited the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was supported by the National Nature Science Foundation of China (31871182), the Chongqing Science and Health joint project (2020MSXM130), and the General Projects of Chongqing Natural Science Foundation (cstc2019jcyj-msxmX0283).
ACKNOWLEDGMENTS

The authors thank all participants in this study. The authors also would like to thank the technical support of the BIOTREE company in Shanghai, China.

REFERENCES

An, Y., Park, S. P., and Kim, Y. K. (2021). Aqueous Humor Inflammatory Cytokine Levels and Choroidal Thickness in Patients with Macular Edema Associated with branch Retinal Vein Occlusion. Int. Ophthalmol., 1–12. doi:10.1007/s10792-021-01798-x

Ashino, H., Shimamura, M., Nakajima, H., Dombou, M., Kawanaka, S., Oikawa, T., et al. (2003). Novel Function of Ascorbic Acid as an Angiostatic Factor. Angiogenisis 6 (4), 259–269. doi:10.1023/b:agen.000029390.09354.8f

Aswani, V., Rajsheel, P., Bapatla, R. B., Sunil, B., and Raghavendra, A. S. (2019). Oxidative Stress Induced in Chloroplasts or Mitochondria Promotes Proline Accumulation in Leaves of Pea (Pisum Sativum): Another Example of Chloroplast-Mitochondria Interactions. Protoplasma 256 (2), 449–457. doi:10.1007/s00709-018-1306-1

Balaratnasingam, C., Inoue, M., Ahn, S., McCann, J., Dhrami-Gavazi, E., Yannuzzi, L. A., et al. (2016). Visual Acuity Is Correlated with the Area of the Foveal Avascular Zone in Diabetic Retinopathy and Retinal Vein Occlusion. Ophthalmology 123, 2352–2367. doi:10.1016/j.ophtha.2016.07.008

Breda, J. B., Sava, A. C., Himmelreich, U., Somers, A., and Stalmans, I. (2020). Metabolomic Profiling Of Aqueous Humor from Glaucoma Patients - The Metabolomics in Surgical Ophthalmological Patients (MISO) Study. Expert. Eye Res. 201 (1), 108268. doi:10.1016/j.exer.2020.108268

Buisset, A., Kohler, P., Leruez, S., Muller, J., Amati-Bonneau, P., Lenaers, G., et al. (2019). Metabolomic Profiling of Aqueous Humor in Glaucoma Points to Taurine and Spermine Deficiency: Findings from the Eye-D Study. J. Proteome Res. doi:10.1021/acs.jproteome.8b00915

Chen, K. H., Hsiang, E. L., Hsu, M. Y., Chou, Y. C., Lin, T. C., Chang, Y. L., et al. (2018). Elevation of Serum Oxidative Stress in Patients with Retinal Vein Occlusion. J. Proteome Res. doi:10.1021/acs.jproteome.8b0036

Han, G., Wei, P., He, M., Teng, H., and Chu, Y. (2020). Metabolomic Profiling of the Aqueous Humor in Patients with Wet Age-Related Macular Degeneration Using UHPLC-MS/MS. J. Proteome Res. 19 (6), 2358–2366. doi:10.1021/acs.jproteome.0c0036

Haskö, G., and Pacher, P. (2012). Regulation of Macrophage Function by Adenosine. A-23 (4), 865–869. doi:10.1161/ajpatha.112.226852

Hwang, D. K., Chang, Y. L., Lin, T. C., Peng, C. H., Chien, K. H., Tsai, C. Y., et al. (2020). Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion. Biomolecules 10 (10), 1414. doi:10.3390/biom1014114

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.762500/full#supplementary-material
Pietrowska, K., D Muchowska, D. A., Krasnicki, P., Bujalska, A., Samczuk, P., Parfeniuk, E., et al. (2018). An Exploratory LC-MS-based Metabolomics Study Reveals Differences in Aqueous Humor Composition between Diabetic and Non-diabetic Patients with Cataract. Electrophoresis 39 (9-10), 1233–1240. doi:10.1002/elps.201700411

Querques, G., Triolo, G., Casalino, G., García-Arumí, J., Badal, J., Zapata, M., et al. (2013). Retinal Venous Occlusions: Diagnosis and Choice of Treatments. Ophthalmic Res. 49 (4), 215–222. doi:10.1159/000346734

Rehak, M., Hollborn, M., Iandiev, I., Pannicke, T., Wiedemann, P., and Bringmann, A. (2010). Inflammatory Factors in Experimental Retinal Vein Occlusion. Acta Ophthalmologica 82 (s2), 0.

Riis-Vestergaard, M. J., Misfeldt, M. W., and Bek, T. (2014). Dual Effects of Adenosine on the Tone of Porcine Retinal Arterioles In Vitro. Ophthalmol. Vis. Sci. 55 (3), 1630–1636. doi:10.1167/ios.13-13428

Santiago, A. R., Madeira, M. H., Boia, R., Aires, I. D., Rodrigues-Neves, A. C., Santos, P. F., et al. (2020). Keep an Eye on Adenosine: Its Role in Retinal Inflammation. Pharmocol. Ther. 210, 107513. doi:10.1016/j.pharmthera.2020.107513

Sebastião, A. M., and Ribeiro, J. A. (2009). Adenosine Receptors and the central Nervous System. Handbook Exp. Pharmacol. 83 (S3uppl. 193), 471–534. doi:10.1007/978-3-540-89615-9_16

Sivanand, S., and Vander Heiden, M. G. (2020). Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer. Cancer Cell 37 (2), 147–156. doi:10.1016/j.ccell.2019.12.011

Tao, M. A., Ti, B., Px, A., Sheng, J. C., Wy, A., Pei, D. A., et al. (2020). UPLC-MS-based Urine Nontargeted Metabolic Profiling Identifies Dysregulation of Pantothenate and CoA Biosynthesis Pathway in Diabetic Kidney Disease - ScienceDirect. Life Sci. 258, 118160. doi:10.1016/j.lfs.2020.118160

Torretta, S., Scaglione, A., Ricci, L., Mainini, F., Di Marco, S., Cuccovillo, I., et al. (2020). D-mannose Suppresses Macrophage IL-1β Production. Nat. Commun. 11 (1), 6343. doi:10.1038/s41467-020-20164-6

Wang, H., Fang, J., Chen, F., Sun, Q., Xu, X., Lin, S. H., et al. (2019). Metabolomic Profile of Diabetic Retinopathy: a GC-TOFMS-Based Approach Using Vitreous and Aqueous Humor. Acta Diabetol. 57 (24), 41–51. doi:10.1007/s00592-019-01363-0

Xu, J., Jakher, Y., and Ahrens-Nicklas, R. C. (2020). Brain Branched-Chain Amino Acids in Maple Syrup Urine Disease: Implications for Neurological Disorders. Int. J. Mol. Sci. 21 (20), 7490. doi:10.3390/ijms21207490

Xu, J., Su, G., Huang, X., Chang, R., and Yang, P. (2021). Metabolomic Analysis of Aqueous Humor Identifies Aberrant Amino Acid and Fatty Acid Metabolism in Vogt-Koyanagi-Harada and Behcet’s Disease. Front. Immunol. 12, 587393. doi:10.3389/fimmu.2021.587393

Yong, H., Qj, H., Yan, H., Wu, Q., and Zuo, L. The Correlation between Cytokine Levels in the Aqueous Humor and the Prognostic Value of Anti-vascular Endothelial Growth Factor Therapy for Treating Macular Edema Resulting from Retinal Vein Occlusion. Graefe’s Archive Clin. Exp. Ophthalmol. 259 (11), 3243–3250. doi:10.1007/s00417-021-05211-2

Zeng, Y., Mtintsilana, A., Goedecke, J. H., Micklefield, L. K., Olsson, T., and Chorrell, E. (2019). Alterations in the Metabolism of Phospholipids, Bile Acids and Branched-Chain Amino Acids Predicts Development of Type 2 Diabetes in Black South African Women: a Prospective Cohort Study. Metabolism 95, 57–64. doi:10.1016/j.metabol.2019.04.001

Zhenyukh, O., Civantos, E., Ruiz-Ortega, M., Soledad Sánchez, M., Vázquez, C., Peiró, C., et al. (2017). High Concentration of Branched-Chain Amino Acids Promotes Oxidative Stress, Inflammation and Migration of Human Peripheral Blood Mononuclear Cells via mTORC1 Activation. Free Radi. Biol. Med. 104, 165–177. doi:10.1016/j.freeradbiomed.2017.01.009

Zizioli, D., Tiso, N., Guglielmi, A., Saraceno, C., Busolin, G., Giuliani, R., et al. (2015). Knock-down of Pantothenate Kinase 2 Severely Affects the Development of the Nervous and Vascular System in Zebrafish, Providing New Insights into PKAN Disease. Neurobiol. Dis. 85 (8), 35–48. doi:10.1016/j.nbd.2015.10.010

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Xiong, Chen, Ma, Zheng, Yang, Chen, Zhou, Pu, Chen and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.